Table 2 Subgroup analyses
From: Prognosis of pregnancy-associated breast cancer: a meta-analysis
Subgroups | No. of Articles (No. of Studies) | HR (95% CI) | Heterogeneity Test | |||
|---|---|---|---|---|---|---|
I2 (%) | P-value | |||||
All studies included | 54 (76) | – | – | – | ||
Diagnosed time | During pregnancy | OS | 13 (14) | 1.46(1.12–1.90) | 73.6 | < 0.001 |
DFS | 7 (7) | 1.30(1.11–1.53) | 26.3 | 0.228 | ||
During postpartum period | OS | 13(13) | 1.97(1.67–2.33) | 49.0 | 0.023 | |
DFS | 2(2) | 1.86(1.17–2.93) | 0.0 | 0.740 | ||
PABC definition | Pregnancy & < 6 months postpartum | OS | 2(2) | 1.37(1.09–1.72) | 0.0 | 0.852 |
Pregnancy & < 12 months postpartum | OS | 20(20) | 1.44(1.20–1.72) | 60.7 | < 0.001 | |
DFS | 8(9) | 1.52(1.27–1.81) | 17.4 | 0.288 | ||
Pregnancy & < 24 months postpartum | OS | 3(3) | 1.42(1.01–2.01) | 67.4 | 0.047 | |
Pregnancy & < 60 months postpartum | OS | 3(3) | 1.48(0.90–2.44) | 65.2 | 0.057 | |
Geographic region | Europe | OS | 15(17) | 1.53(1.26–1.86) | 71.1 | < 0.001 |
DFS | 9(9) | 1.32(1.15–1.52) | 8.7 | 0.363 | ||
North America | OS | 16(17) | 1.38 (1.17–1.63) | 53.2 | 0.005 | |
DFS | 5(6) | 1.68(1.35–2.08) | 15.5 | 0.315 | ||
Asia | OS | 9(9) | 1.42(1.09–1.85) | 60.0 | 0.010 | |
Others | OS | 2(2) | 1.55(1.13–2.13) | 0.0 | 0.544 | |
Year of publication | Before 2000 | OS | 11(13) | 1.46(1.18–1.82) | 45.4 | 0.038 |
DFS | 3(3) | 1.27(0.97–1.72) | 50.7 | 0.107 | ||
2000–2010 | OS | 11(12) | 1.48(1.19–1.85) | 79.0 | < 0.001 | |
DFS | 4(5) | 1.40(1.14–1.71) | 20.5 | 0.284 | ||
2011–2019 | OS | 20(20) | 1.43(1.20–1.72) | 62.7 | < 0.001 | |
DFS | 11(11) | 1.50(1.29–1.76) | 11.5 | 0.334 | ||
HR estimate | Paper report | OS | 24(25) | 1.42(1.22–1.65) | 73.1 | < 0.001 |
DFS | 12(12) | 1.35(1.19–1.53) | 29.1 | 0.160 | ||
Indirect | OS | 19(20) | 1.43(1.28–1.60) | 47.4 | 0.010 | |
DFS | 7(8) | 1.48(1.22–1.79) | 24.7 | 0.232 | ||